Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects

NCT02456844 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02456844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02456844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
July 31, 2015
Enrollment
24 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis